Greenwich LifeSciences, Inc.
NASDAQ: GLSI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Snehal S. Patel
- Employees
- 4
- Headquarters
- Stafford, United States
- IPO year
- 2020
- Market cap
- $315.9M
- Website
- https://greenwichlifesciences.com
Loading GLSI…
Loading profile data…Frequently asked questions about GLSI
What does Greenwich LifeSciences, Inc. (GLSI) do?
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase I...
Where does GLSI trade?
Greenwich LifeSciences, Inc. (GLSI) trades on the NASDAQ Capital Market.
What sector is GLSI in?
Greenwich LifeSciences, Inc. (GLSI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Greenwich LifeSciences, Inc.?
Snehal S. Patel is the chief executive officer of Greenwich LifeSciences, Inc. (GLSI).
Where is Greenwich LifeSciences, Inc. headquartered?
Greenwich LifeSciences, Inc. is headquartered in United States.
Does GLSI pay a dividend?
Greenwich LifeSciences, Inc. (GLSI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GLSI go public?
Greenwich LifeSciences, Inc. (GLSI) completed its initial public offering in 2020.